CBD Health Shop NEWRY

28/05/2026

06/05/2026

Medical cannabis is changing lives daily

Billy is celebrating three years seizure freedom! Yes…. three whole years! ZERO seizures, thanks to prescription cannabis.

Not only are his seizures gone,
Not only is he aware, alert, present, curious, and interactive, he is absolutely happy. He is vibrant.
He is filled with laughter and doesn’t want to sleep.
He is talkative and playful.

I have gotten my boy back.
After years of constant seizures he has now went three whole years = ZERO seizures.
Prescription cannabis is doing its job. It is working the way it’s supposed to. We have finally found something to help Billy.

I know this can all change in an instant, but I needed to share this with you all.

We are alive and well and Billy is not only doing good he is doing great and we love you all so very much!

Charlotte 💜

03/05/2026

Best medicine on the planet

02/05/2026

In November 2024, researchers published the study "Alterations of Endocannabinoid Signaling and Microglia Reactivity in the Retinas of AD-like Mice Precede the Onset of Hippocampal β-Amyloid Plaques" in the Journal of Neurochemistry. The study explored how the retina, often called a "window to the brain," could reveal early signs of Alzheimer’s disease (AD).
The team examined endocannabinoid system (ECS) changes and microglial activity—immune cells of the nervous system—in a mouse AD model before significant brain changes, like β-amyloid plaques, developed. They focused on how these processes could contribute to neuroinflammation and oxidative stress, which are hallmark early events in Alzheimer’s pathology.
To conduct this research, the scientists used a genetically modified mouse model known as Tg2576, mimicking some aspects of Alzheimer’s disease. They focused on 12-month-old mice, a stage when β-amyloid plaques have not yet formed in the brain. Using advanced lab techniques, they analyzed the retinas of these mice for signs of inflammation, changes in ECS components, and oxidative stress markers.
Their work revealed increased numbers of microglia, indicating early retinal inflammation and elevated oxidative stress but no significant neuronal degeneration or retinal thinning.
The study found key alterations in the ECS, particularly in the levels of 2-arachidonoylglycerol (2-AG), an important signaling molecule. The researchers discovered a significant decrease in 2-AG levels in the retinas of AD-like mice, accompanied by an increase in the enzyme MAGL, which breaks down 2-AG. This imbalance, combined with increased levels of the CB2 receptor (linked to inflammation), suggests the ECS is dysregulated in AD.
Interestingly, these changes occurred in the retina before β-amyloid plaques appeared in the brain, reinforcing that the retina reflects early Alzheimer ’s-related changes.
The study also highlighted the role of microglia, immune cells in the retina that can influence inflammation and neuronal health. In AD-like mice, microglia numbers were significantly higher compared to healthy mice, suggesting these cells are reacting to early signs of damage or stress. Despite this, there were no significant changes in glutamate levels—a neurotransmitter often linked to cell damage—indicating that retinal neurons might still function normally at this stage.
These findings support the potential use of the retina as a non-invasive tool to detect AD before brain damage becomes severe. By identifying ECS dysregulation and inflammation as early markers, the study opens the door for exploring new therapies targeting these pathways to slow or prevent AD progression.
-Mike Robinson, founder Global Cannabinoid Research Center, The Researcher OG

29/04/2026

*RELAX CHILL DESTRESS* THC/CBD VAPES AVAILABLE. £40 EACH OR 2 FOR £75

20/04/2026

Pain patients often don’t just need stronger signal blocking; they need better internal regulation so the whole pain system stops running hot. The 2024 review, "The endocannabinoid system as a therapeutic target in neuropathic pain: a review" (2024), laid out the ECS as a real regulator of neuropathic pain across peripheral, spinal, and supraspinal pathways, which is why cannabinoids may help by modulating the system that processes pain instead of only trying to shut the signal down.

That difference matters. Opioids mainly reduce excitatory neurotransmitter release through mu, kappa, and delta opioid receptor activity, and they change pain perception in the brain while raising pain threshold in the spinal cord.

Cannabinoids also decrease neurotransmitter release, but they additionally activate descending inhibitory pain pathways, reduce postsynaptic sensitivity, and help regulate neural inflammation, which makes them more about reading, modulating, and recalibrating pain traffic than simply putting a blanket over it.

That’s why ECS balance matters so much in chronic pain. The 2024 review notes that the ECS is expressed throughout the ascending and descending pain pathways, that CB2 signaling is especially relevant in inflammatory and neuropathic states, and that local endocannabinoid levels and cannabinoid receptor expression can increase in response to injury or disease as part of a protective analgesic response.

In plain language, the body is already trying to regulate pain from the inside, and cannabinoids may work better when they support that balancing network instead of replacing it with one blunt force strategy.

So the sharper way to say it is this - opioids can block pain signals, but cannabinoids help interpret, regulate, and cool the environment those signals are moving through. That’s a different kind of pain medicine, and for many patients it may be the difference between temporary suppression and better internal balance.

-Mike Robinson Researcher OG

Study: https://www.tandfonline.com/doi/abs/10.1080/14728222.2024.2407824